Hansa Biopharma

Hansa Medical is a biopharmaceutical company focusing on novel immunomodulatory enzymes. The lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Additional projects focus on development of new antibody modulating enzymes, as well as HBP, a diagnostic biomarker for prediction of severe sepsis at emergency departments that is already introduced on the market. The company is based in Lund, Sweden. Hansa Medical’s share (ticker: HMED) is listed on Nasdaq Stockholm. Hansa Medicals’ strong research background in inflammation has also led to invention and market introduction of a novel in vitro diagnostic method for the prediction of severe sepsis. Collaboration partner Axis-Shield Diagnostics markets the product, HBP-assay.